A Phase 1, Non-randomized, Open-label, Single Dose Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics, Safety And Tolerability Of Rivipansel (Pf-06460031) In Subjects With Renal Impairment And In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Rivipansel (Primary)
- Indications Haematological malignancies; Sickle cell anaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 03 Aug 2017 Planned End Date changed from 10 Aug 2017 to 1 Aug 2017.
- 03 Aug 2017 Planned primary completion date changed from 14 Jul 2017 to 1 Jul 2017.
- 18 May 2017 Planned End Date changed from 1 Jul 2017 to 10 Aug 2017.